Research programme: PDE IV inhibitors - elbion NV
Latest Information Update: 22 Aug 2007
At a glance
- Originator elbion NV
- Mechanism of Action Type 4 cyclic nucleotide phosphodiesterase inhibitors
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
Highest Development Phases
- No development reported Inflammation
Most Recent Events
- 05 Dec 2006 4AZA Bioscience has merged with elbion to form elbion NV
- 02 Dec 2005 Preclinical trials in Inflammation in Belgium (unspecified route)